Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients

(2015) H. Reikvam et al.   CELL PROLIFERATION

Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells

(2015) Håkon Reikvam et al.   Oncotarget

Discovery of New Inhibitors of Cdc25B Dual Specificity Phosphatases by Structure-Based Virtual Screening

(2012) Antonio Lavecchia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies

(2012) Lise Willems et al.   Current Oncology Reports

Cysteine 81 Is Critical for the Interaction of S100A4 and Myosin-IIA

(2011) Natalya G. Dulyaninova et al.   BIOCHEMISTRY

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention

(2011) Håkon Reikvam et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combined Inhibition of PI3K and mTOR Exerts Synergistic Antiproliferative Effect, but Diminishes Differentiative Properties of Rapamycin in Acute Myeloid Leukemia Cells

(2011) Josko Mise et al.   PATHOLOGY & ONCOLOGY RESEARCH

Transcriptional Repression of Cdc25B by IER5 Inhibits the Proliferation of Leukemic Progenitor Cells through NF-YB and p300 in Acute Myeloid Leukemia

(2011) Satoki Nakamura et al.   PLoS One

The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia

(2010) S. Nakamura et al.   CARCINOGENESIS

βTrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit

(2010) Yann Thomas et al.   CELL CYCLE

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity

(2010) Øystein Bruserud et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

CDC25B Mediates Rapamycin-Induced Oncogenic Responses in Cancer Cells

(2009) R.-q. Chen et al.   CANCER RESEARCH

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

(2009) A. E. Perl et al.   CLINICAL CANCER RESEARCH

Targeted therapy in acute myeloid leukaemia: current status and future directions

(2009) Camilla Stapnes et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

(2009) S. Park et al.   HAEMATOLOGICA

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress

(2008) C Didier et al.   ONCOGENE

Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety

(2008) B. Lowenberg   Hematology-American Society of Hematology Education Program